Buying its own future output: the company is spending now to own more of the value it already helps create
The model's full reasoning — Q3 2021 call → NOWe need answer YES or NO. Need analyze transcript. Question: Does management describe company currently moving itself further up/down value chain — taking ownership/direct control of step that someone else used to perform, own, capture margin — and convey move already being executed and already changing what company earns/can do, rather than planned/contemplated? Need use only transcript. Need identify if management describes vertical integration in motion. Let's parse. Company Alignment Healthcare, Medicare Advantage plan. They have AVA platform, Care Anywhere clinical teams. They talk about payvider model. They have internal clinical teams, provider partners. They mention DCE (Direct Contracting Entity) program. They are taking risk for CMS fee-for-service beneficiaries. Is that vertical integration? They are a health plan, but DCE is taking over risk from CMS? Hmm. Question asks "currently moving itself further up or down its own value chain — taking ownership or direct control of a step in the chain that someone else used to perform, own, or capture the margin on". Need see if management describes such. Transcript: John Kao talks about AVA platform, Care Anywhere clinical teams, business intelligence. "Our payvider operating model is powered by proprietary AVA platform, our care or clinical teams and business intelligence tools." Payvider suggests combining payer and provider. They have internal clinical teams (Care Anywhere) that manage high-risk population. They are a health plan (payer) and also provide care (provider). Is that vertical integration? They are taking on care delivery that previously was done by external providers? They have "internal clinical teams" and "external provider partners." They use Care Anywhere clinical teams to manage high-risk population. They have "patient panel management module" to optimize deployment of clinicians. They run inpatient admissions etc. They have "Care Anywhere care model" delivering holistic care. This could be internalizing care management/clinical services. But is it "currently moving" and "already being executed"? They describe existing model, not new move.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| KNDI | Kandi Technologies Group, Inc. | Q2 2021 | 2021-08-09 | F |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
FLEX · Q1 2018 → YESThe question is about whether Flex Ltd is currently moving itself further up or down its own value chain by taking ownership or control of a step that someone else used to perform. YES The transcript shows Flex is actively internalizing a previously external step in the shoe manufacturing value chain by taking ownership of automation, process redesign, and end-to-end production for Nike. Management describes this as an ongoing, real-time execution: “we’re vertically integrating technologies,” “rethinking all of the whole supply process we’re applying automation technologies,” “we’ve manufactured over 1 million pairs,” and “we took over the facility in September” for Bose, with the Nike factory transition “complete by October.” They explain the value capture: the company now keeps margin it previously paid away, controls quality, cost, supply, and timing previously constrained by a counterparty, and serves customers it could not reach through the old chain. While acknowledging the ramp is early (losses persist through Q2, breakeven expected by year-end), the move is already changing what Flex earns and can do, not merely planned or contemplated. This meets all three required elements.
XOM · Q2 2018 → YESThe question is about whether ExxonMobil is currently moving itself further up or down its own value chain by taking ownership or control of a step that someone else used to perform. YES The transcript shows ExxonMobil actively internalizing logistics and supply-chain steps that previously required external partners or intermediaries. Neil Chapman explicitly states they “will get engaged in the connectivity between the Permian and our Gulf Coast refining and chemical assets,” with equity participation in logistics, the Wink terminal acquisition (closed late 2017), 11 active completion crews, and a signed letter of intent for a 1 million bpd long-haul crude pipeline. These moves are already producing results: Gulf Coast refineries are “already processing our production levels and more, capturing the benefits of disadvantaged feed cost.
KMDA · Q2 2023 → YESThe question is about whether management describes the company currently moving itself further up or down its own value chain, taking ownership of a step that someone else used to perform, and that th...YES The transcript shows management describing the 2021 acquisition of the Beaumont plasma collection center as the company's entry into U.S. plasma collection, with the explicit goal of becoming a "fully integrated specialty plasma product company." They state they are "successfully expanding" capacity at the first center (already acquired and operational) and plan to open the second in Houston in early 2024. This is presented as an active, ongoing move to internalize plasma collection that previously depended on external suppliers.